Pharmaceutical company Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 9.9% year on year to $796.2 million. The company’s full-year revenue guidance of $3.15 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $0.30 per share was 30.3% above analysts’ consensus estimates.
Is now the time to buy AMRX? Find out in our full research report (it’s free for active Edge members).
Amneal (AMRX) Q2 CY2026 Highlights:
- Revenue: $796.2 million vs analyst estimates of $768.2 million (9.9% year-on-year growth, 3.6% beat)
- Adjusted EPS: $0.30 vs analyst estimates of $0.23 (30.3% beat)
- Adjusted EBITDA: $206.5 million vs analyst estimates of $180.6 million (25.9% margin, 14.3% beat)
- The company lifted its revenue guidance for the full year to $3.15 billion at the midpoint from $3.1 billion, a 1.6% increase
- Management slightly raised its full-year Adjusted EPS guidance to $1.01 at the midpoint
- EBITDA guidance for the full year is $765 million at the midpoint, above analyst estimates of $748.8 million
- Operating Margin: 16.3%, in line with the same quarter last year
- Market Capitalization: $5.90 billion
StockStory’s Take
Amneal’s second quarter results reflected ongoing momentum driven by expanded product launches and strength across its core Affordable Medicines and Specialty segments. However, the market reacted negatively despite the company’s revenue and non-GAAP profit both surpassing Wall Street’s expectations. Management attributed growth to robust demand for transdermal patches in Women’s Health, increased uptake of new complex generics, and the continued success of branded products like CREXONT and BREKIYA. Co-CEO Chirag Patel noted, “The scale of opportunity in front of us today has never been greater,” highlighting recent approvals and pipeline advances as central to performance.
Looking forward, management’s raised guidance is underpinned by several major initiatives, including the pending Kashiv Biosciences acquisition, which is expected to establish Amneal as a fully integrated biosimilars player. The company’s outlook is also supported by anticipated launches in high-value complex generics like lanreotide, expanding capacity for in-demand women’s health products, and further growth in branded neurology therapies. CFO Anastasios Konidaris emphasized, “We expect this momentum to continue through the balance of 2026 and into 2027 and beyond,” while noting investments in manufacturing and R&D as key enablers of the company’s growth strategy.
Key Insights from Management’s Remarks
Management emphasized that second quarter performance was shaped by strong execution in complex generics, Specialty brands, and operational efficiency, with new product launches and supply chain resilience standing out as differentiators.
- Complex generics momentum: Amneal’s strategy of prioritizing complex generics and differentiated dosage forms, such as injectables and ophthalmics, led to multiple high-value launches and approvals—including romidepsin in oncology and expansion in iohexol presentations—demonstrating the payoff from years of R&D investment.
- Women’s health surge: Demand for transdermal patches rose significantly following revised FDA guidance, driving management to expand production capacity in the U.S. Rapid growth in this segment was cited as a core driver, with the company working to triple output to meet heightened market needs.
- Specialty brand traction: Key branded products, including CREXONT for Parkinson’s and BREKIYA for migraine and cluster headache, exceeded internal expectations. Management highlighted strong uptake and favorable Phase IV data for CREXONT, with 80% of prescriptions coming from general neurologists—a shift from prior market patterns.
- Biosimilars platform expansion: The pending Kashiv acquisition is positioned as transformative, giving Amneal end-to-end biologics capabilities and expanding its biosimilars pipeline. Management pointed to the ability to advance multiple biosimilar molecules with limited competition, targeting products like XOLAIR and ORENCIA.
- Operational resilience and efficiency: Digitization and AI-driven automation in manufacturing, along with supply chain improvements, allowed Amneal to respond effectively to challenges—including a recent flood at its Gujarat facility in India—minimizing disruptions and enabling continued revenue growth.
Drivers of Future Performance
Amneal’s guidance for the remainder of the year centers on execution in product launches, biosimilars integration, and capacity expansion amid evolving regulatory and market dynamics.
- Biosimilars integration and pipeline: The Kashiv acquisition is expected to enable Amneal to launch six commercial biosimilars by next year, addressing a market exceeding $14 billion. Management sees sustainable growth from a pipeline focused on molecules with limited competition and long exclusivity periods, while the integration is also expected to bring cost synergies and financial benefits.
- Complex generics and new launches: Upcoming launches of high-value, technically challenging generics like lanreotide and additional iohexol SKUs are projected to drive revenue growth. Management anticipates that these products, supported by enhanced U.S. manufacturing, will benefit from both high demand and supply constraints in the market.
- Manufacturing expansion and risk factors: Investments to increase capacity for women’s health patches and injectables are intended to capture growing market demand. However, management acknowledged potential risks from regulatory changes, tariffs, and supply chain disruptions, emphasizing ongoing efforts to mitigate these through increased U.S. production and close FDA engagement.
Catalysts in Upcoming Quarters
Looking ahead, our analysts will be watching (1) the successful integration and commercial execution of the Kashiv biosimilars platform, (2) regulatory progress and market uptake for upcoming launches like lanreotide and additional complex generics, and (3) the pace and impact of expanded manufacturing capacity for transdermal patches and injectables. Additionally, the evolution of tariff policy and FDA feedback on key pipeline assets remain important signposts.
Amneal currently trades at $18.40, down from $19.10 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
